Cameron, Elizabeth M; Spencer, Sade; Lazarini, Jonathan et al. (2009) Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol 213:123-30
|
Lambracht-Washington, Doris; O'Connor, Kevin C; Cameron, Elizabeth M et al. (2007) Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J Neuroimmunol 186:164-76
|
Harp, Christopher; Lee, Jane; Lambracht-Washington, Doris et al. (2007) Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. J Neuroimmunol 183:189-99
|
Biegler, Brian W; Yan, Shirley X; Ortega, Sterling B et al. (2006) Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol 180:159-71
|
Ratts, Robert B; Lovett-Racke, Amy E; Choy, Judy et al. (2006) CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol 178:117-29
|
Tennakoon, Deepani K; Mehta, Riyaz S; Ortega, Sterling B et al. (2006) Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 176:7119-29
|
Ratts, Robert B; Karandikar, Nitin J; Hussain, Rehana Z et al. (2006) Phenotypic characterization of autoreactive T cells in multiple sclerosis. J Neuroimmunol 178:100-10
|
Monson, Nancy L; Brezinschek, Hans-Peter; Brezinschek, Ruth I et al. (2005) Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol 158:170-81
|
Crawford, Michael P; Yan, Shirley X; Ortega, Sterling B et al. (2004) High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103:4222-31
|
Karandikar, Nitin J; Crawford, Michael P; Yan, Xiao et al. (2002) Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 109:641-9
|